#theclear

Oregon and Colorado are currently the only U.S. states with statewide frameworks allowing regulated psilocybin services. These programs are often misunderstood as “legalization,” but state officials stress that they operate as tightly controlled public health models and do not override federal law. Oregon established the first statewide program through Measure 109, approved by voters in 2020. The program …

Oregon and Colorado Psilocybin Programs Explained Read More »

Psilocybin remains illegal under United States federal law. It is classified as a Schedule I substance under the Controlled Substances Act, meaning it is defined as having no currently accepted medical use and a high potential for abuse. This classification applies regardless of state or local policy changes and makes non-research possession, distribution, or manufacturing …

Psilocybin Legal Status in the United States Read More »

One of the most serious safety risks associated with mushrooms is misidentification. Many toxic mushroom species closely resemble psilocybin-containing mushrooms, making visual identification unreliable. Public health agencies emphasize that accidental ingestion of poisonous mushrooms can result in severe illness, organ failure, or death (Centers for Disease Control and Prevention). Several deadly mushroom species, including Amanita …

Mushroom Misidentification and Environmental Risks Read More »

In psilocybin research, scientists often refer to the concepts of “set” and “setting” when discussing psychological safety and variability in outcomes. These terms describe the internal and external factors that influence how individuals respond during clinical studies. Researchers emphasize that understanding set and setting is essential for minimizing risk and interpreting research results accurately (National …

Set and Setting in Psilocybin Research Read More »

Psychological safety is one of the primary concerns in psilocybin research. While studies are designed to minimize harm, researchers consistently report that psilocybin can produce intense psychological experiences that are not appropriate for all individuals. For this reason, modern research places strong emphasis on identifying contraindications and understanding who may be at higher risk (National …

Psychological Risks and Contraindications of Psilocybin Read More »

Safety is a central focus of all modern psilocybin research. While scientific interest in psilocybin has increased, researchers consistently stress that the compound carries risks and must be studied under controlled conditions. Public health agencies emphasize that understanding potential harms is just as important as understanding potential outcomes (National Institute on Drug Abuse). One of …

Psilocybin Safety and Risk Awareness Read More »

In clinical research, integration and follow-up are essential components of psilocybin therapy models. Researchers emphasize that observed outcomes are not measured during supervised sessions alone, but through structured follow-up that assesses psychological well-being, safety, and long-term effects. These stages help distinguish short-term responses from lasting changes and ensure responsible data collection (U.S. Food and Drug …

Integration and Follow-Up in Psilocybin Clinical Studies Read More »

Supervision is a core component of all modern psilocybin clinical research. Because psilocybin can temporarily alter perception, mood, and cognition, studies are designed to ensure participants are continuously supported and monitored by trained professionals. Researchers emphasize that supervision is not optional but a foundational requirement for ethical and scientific validity (U.S. Food and Drug Administration). …

Supervision and Ethical Safeguards in Psilocybin Clinical Studies Read More »

In psilocybin research, preparation and screening are foundational components of clinical study design. Researchers emphasize that these steps are critical for participant safety, data quality, and ethical responsibility. Unlike observational studies, psilocybin trials involve extensive evaluation before any intervention occurs (U.S. Food and Drug Administration). Screening typically begins with medical evaluation. Researchers assess physical health, …

Preparation and Screening in Psilocybin Clinical Studies Read More »

In modern research, psilocybin is never studied in isolation. Clinical trials use structured therapy models designed to support participant safety, data consistency, and ethical oversight. Researchers emphasize that outcomes observed in studies are closely tied to these frameworks rather than the compound alone (U.S. Food and Drug Administration). Most psilocybin therapy models follow a multi-phase …

How Psilocybin Therapy Models Are Structured Read More »